(HealthDay News) — A type of breast implant linked to cancer can still be sold in the United States, the U.S. Food and Drug Administration said Thursday.
The agency said it is too soon to ban a type of textured implant recently linked to anaplastic large-cell lymphoma and noted that these kinds of implants account for less than 10 percent of the U.S. market.
The decision comes after a public meeting in March where dozens of women called for stronger breast implant safety measures. The FDA said women should be given more information about the implants and is considering new patient warnings and checklists for the implants.
“There has been a growing discussion in recent months around the safety of certain breast implants, with regulatory agencies around the world weighing the risk of breast implant-associated anaplastic large cell lymphoma,” according to a statement issued by the FDA. “It’s an issue that has been a priority for us at the U.S. Food and Drug Administration since 2011 when we warned women that the available information at the time indicated that there is a risk for women with breast implants, especially those with textured implants, for developing this disease.”